KPMA voices strong opposition to government's generic price-cut proposal

The industry association of domestic drug makers, the Korea Pharmaceutical Manufacturers Association (KPMA), has repeatedly stressed on its opposition against the government's price-cutting attempt.

The KPMA noted that the price reform is expected to cause about 3 trillion won losses in the industry from 2011 to 2013.

So far, the details of the reform proposal have not been officially rev...